Glucophage Xr (Metformin Hydrochloride)

Glucophage XR is indicated for the long‑term management of type 2 diabetes mellitus in adults.

• As monotherapy in patients whose diet and exercise do not achieve glycemic control.
• In combination with other oral antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors.
• As part of a comprehensive treatment plan that includes lifestyle modification.
• For patients with renal function within recommended limits to reduce risk of lactic acidosis.
• To improve insulin sensitivity in peripheral tissues.

The safety profile of Glucophage XR includes a range of adverse events that are categorized by frequency and severity.

Common

• Gastrointestinal upset such as nausea, abdominal discomfort, or diarrhea.
• Metallic taste in the mouth.
• Decreased appetite or weight loss.
• Mild headache.

Serious

• Lactic acidosis, a rare but potentially fatal metabolic complication.
• Severe hypoglycemia when used with insulin or insulin secretagogues.
• Hepatotoxicity presenting as elevated liver enzymes.
• Skin reactions such as rash or Stevens‑Johnson syndrome.

Before prescribing Glucophage XR, clinicians should evaluate several patient‑specific factors to minimize risks.

• Assess renal function; avoid use in patients with eGFR below the recommended threshold.
• Review hepatic status, as liver disease can increase the risk of lactic acidosis.
• Consider pregnancy and lactation status; the drug is category B but should be used only if benefits outweigh risks.
• Monitor vitamin B12 levels during long‑term therapy, as deficiency may develop.
• Advise patients to avoid excessive alcohol consumption, which can potentiate lactic acidosis.
• Ensure proper dosing schedule to maintain extended‑release formulation integrity.

Glucophage XR may interact with other medicines, altering its effectiveness or increasing adverse effects.

Avoid

• Concomitant use with iodinated contrast agents for imaging studies without appropriate renal monitoring.
• Co‑administration with potent CYP450 inhibitors that significantly raise metformin plasma levels (e.g., cimetidine).
• Use with other agents known to cause lactic acidosis, such as certain antiretrovirals.

Use with caution

• Combination with insulin or insulin secretagogues, which can increase hypoglycemia risk.
• Concurrent use of diuretics that may affect renal function and metformin clearance.
• Co‑administration with drugs that affect vitamin B12 absorption, such as proton pump inhibitors.
• Use with other oral antidiabetics, requiring dose adjustments and close glucose monitoring.